Anixa Biosciences Inc ANIX
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Anixa Biosciences Inc (ANIX) is a healthcare company listed in the US with a market value of about $91M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -43%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.
About Anixa Biosciences
Anixa Biosciences is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $4M in 2014 to $210000 in 2024, a decline of about 24.9% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 7% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $210000 | $210000 | — | $512000 | — | $250000 | $1M | $362500 | $300000 |
| Net income | -$11M | -$13M | -$10M | -$14M | -$13M | -$10M | -$12M | -$14M | -$5M | -$5M |
| Free cash flow | — | — | — | — | — | -$6M | -$5M | -$4M | -$4M | -$4M |
| EPS (diluted) | $-0.34 | $-0.39 | $-0.32 | $0.45 | $-450.00 | $-450.00 | $-590.00 | $-790.00 | $-580.00 | $-570.00 |
| Net margin | — | -5978.1% | -4671.9% | — | -2530.1% | — | -4658.8% | -1258.1% | -1381.8% | -1672.1% |
| ROIC | -60.2% | -54.0% | -35.5% | -37.5% | -29.1% | -89.4% | -179.4% | -207.7% | -60.6% | -244.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Anixa Biosciences stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Anixa Biosciences pay a dividend?
Not currently.
Is Anixa Biosciences a good stock to buy?
We do not give buy or sell advice. Anixa Biosciences scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.